chevron_leftBack
As of 24 April 2025, Takeda Pharmaceutical Company Ltd. has a market cap of $46.11B USD, ranking #431 globally and #24 in Japan. It ranks #42 in the Healthcare sector, and #5 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$46.11BUSD
6.6T JPY
Enterprise Value
$80.62BUSD
11.54T JPY
Revenue (TTM)
$32.0BUSD
4.58T JPY
EBITDA (TTM)
$8.84BUSD
1.26T JPY
Net Income (TTM)
$1.45BUSD
208.07B JPY
EBITDA Margin
28%
Profit Margin
4.5%
PE Ratio
33.3
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Christophe Weber
open_in_new
Employees
49,281
Founded
1781
Website
takeda.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.7% | 3.4% | -4.8% | 7.3% | 1.8% | 4.9% |
Upcoming Earnings
Earnings Date
Thu, May 8
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4502
武田薬品工業
ISIN: JP3463000004
Shares Out.:
Shares Outstanding:
1.585B1
Shares Float:
1.537B2
|
4.33K JPY | |
|
0A87
武田薬品工業 ADR
ISIN: US8740602052
Shares Out.:
Shares Outstanding:
3.17B1
Shares Float:
3.17B2
|
13.93 USD | |
|
NYSE
MIC: XNYS
|
TAK
武田薬品工業 ADR
ISIN: US8740602052
Shares Out.:
Shares Outstanding:
3.17B1
Shares Float:
3.17B2
|
15.18 USD |
|
TKPHF
武田薬品工業
ISIN: JP3463000004
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
32.13 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Takeda Pharmaceutical Company Ltd.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
